Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 4/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677850 | 0.85 | LMNA (0.38) | PNP | |
| SCHEMBL15798435 | 0.76 | KMT2A (0.44) | KMT2ATDP1KDM3BPNPHPRT1 | |
| SCHEMBL29100444 | 0.74 | KMT2A (0.45) | KMT2ATDP1KDM3BPNP | |
| SCHEMBL1227831 | 0.65 | KMT2A (0.62) | KMT2ATDP1KDM3BUBE2N | |
| SCHEMBL153162 | 0.64 | KMT2A (0.73) | KMT2ATDP1KDM3B | |
| SCHEMBL5618617 | 0.63 | CHRM2 (0.61) | KMT2A | |
| SCHEMBL28991875 | 0.62 | GAA (0.46) | — | |
| SCHEMBL29007135 | 0.62 | KMT2A (0.54) | KMT2ATDP1KDM3BUBE2N | |
| SCHEMBL1805336 | 0.61 | PTGS1 (0.45) | — | |
| SCHEMBL1981396 | 0.60 | MEN1 (0.59) | KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4687990-A1 | METHOD OF SYNTHESIS OF TARGETED LIPID NANOPARTICLE AND USES THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4665390-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | Pfizer Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4662196-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661910-A2 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4658809-A1 | CAPPING ASSAY | Seqirus Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250332245-A1 | IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA | PFIZER INC. (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4637717-A1 | LIPID PARTICLE COMPOSITIONS AND METHODS OF USE THEREOF | Pfizer Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4637838-A1 | LIPID NANOPARTICLE COMPOSITION | Seqirus Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2023067560-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067561-A1 | IONIZABLE CATIONIC LIPID FOR MESSENGER RNA DELIVERY | Seqirus Inc. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023057930-A1 | IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF | PFIZER INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023053017-A2 | IONIZABLE CATIONIC COMPOUNDS FOR MESSENGER RNA DELIVERY | Seqirus Inc. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023053016-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220362372-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | PFIZER INC. | 2022-11-17 | — | — | US | disclosed |
| WO-2022234417-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | PFIZER INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022234416-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022234405-A1 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | PFIZER INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022101461-A1 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | BioNTech SE (DE) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332245-A1 | IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA | HAVCR2, RNASEH1, ADAR | KMT2A 3571/4885TDP1 619/4885KDM3B 4393/4885 |
| US-20220362372-A1 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | RNASEH1, HAVCR2, HNRNPH3 | KMT2A 3179/4885TDP1 1120/4885KDM3B 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.